Abstract:Both autophagy and apoptosis are essential processes participating in cell death and maintain cellular homeostasis.The dysregulation of these two biological processes results in development of diseases including cancers.Therefore, targeting nodes of crosstalk between apoptosis and autophagy is a potential strategy for cancer therapy.Melanoma is the most lethal skin cancer accounting for over 80% of skin cancer deaths.We previously identified tumor necrosis factor receptor-associated factor 6 (TRAF6) was overexpressed in melanoma and involved in the malignant phenotype of melanoma cells.Additionally, TRAF6 promotes the activation of fibroblasts to cancer-associated fibroblasts in melanoma.However, the role of TRAF6 in the autophagy and apoptosis remains unclear.In this study, we found that knockdown of TRAF6 significantly induced both apoptosis and autophagy in melanoma cells.The percentage of apoptotic cells elevated nearly three more times after knocking down of TRAF6.Moreover, lots of autophagosomes were observed in TRAF6-deficient melanoma cells.Then we analyzed the transcriptomics data and found the decrease of autophagy related 16 like 2 (ATG16L2) in TRAF6-deficient melanoma cells.Real-time PCR further verify the alteration.Interestingly, knockdown of ATG16L2 resulted in elevated autophagy and apoptosis in melanoma cells.To investigate the mechanism of TRAF6 in regulating ATG16L2, luciferase assay and chromatin immunoprecipitation were performed.The results confirmed that knockdown of TRAF6 inhibited the abundance of c-Jun in the nucleus, which suppressed the transcription activity of ATG16L2.Next, we found cinchonine, a TRAF6 inhibitor, induced autophagy and apoptosis of melanoma cells.In vitro and in vivo studies suggested that cinchonine suppressed the growth of melanoma.Further mechanism studies indicated that cinchonine inhibited the TRAF6/c-Jun/ATG16L2 signaling pathway.Our results suggest that targeting TRAF6/c-Jun/ATG16L2 axis is a promising strategy for melanoma therapy.

Overexpression of Annexin II Receptor-Induced Autophagy Protects Against Apoptosis in Uveal Melanoma Cells

Inhibitory Effects of Telomerase Inhibitor to the Growth of Uveal Melanoma Cells

Zeaxanthin Induces Apoptosis in Human Uveal Melanoma Cells through Bcl-2 Family Proteins and Intrinsic Apoptosis Pathway

BRAF V600E-dependent Role of Autophagy in Uveal Melanoma

The Role of Autophagy in Human Uveal Melanoma and the Development of Potential Disease Biomarkers and Novel Therapeutic Paradigms

Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma

Anti-cancer activity of Annexin V in murine melanoma model by suppressing tumor angiogenesis.

Involvement of autophagy in recombinant human arginase-induced cell apoptosis and growth inhibition of malignant melanoma cells

The multiple roles of autophagy in uveal melanoma and the microenvironment

The Pharmacological Nf-Kappa B Inhibitor Bay11-7082 Induces Cell Apoptosis And Inhibits The Migration Of Human Uveal Melanoma Cells

Study of Cinobufagin As a Promising Anticancer Agent in Uveal Melanoma Through Intrinsic Apoptosis Pathway

1225 WITHDRAWN

The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells

Apoptosis-inducing Effect of Annexin A2 on Multiple Myeloma Cells and Its Related Mechanisms

Apoptosis Induced by Ursodeoxycholic Acid in Human Melanoma Cells Through the Mitochondrial Pathway

Role of Microrna-182 in Posterior Uveal Melanoma: Regulation of Tumor Development Through MITF, BCL2 and Cyclin D2.

Role of ubenimex as an anticancer drug and its synergistic effect with Akt inhibitor in human A375 and A2058 cells.

Overexpression of Annexin II Affects the Proliferation, Apoptosis, Invasion and Production of Proangiogenic Factors in Multiple Myeloma

The Anti-malarial Drug Artesunate Blocks Wnt/β-catenin Pathway and Inhibits Growth, Migration and Invasion of Uveal Melanoma Cells

The BET inhibitor JQ1 suppresses tumor survival by ABCB5-mediated autophagy in uveal melanoma

TRAF6 regulates autophagy and apoptosis of melanoma cells through c-Jun/ATG16L2 signaling pathway